| 29.2 0.01 (0.03%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.82  |
1-year : | 53.05 |
| Resists | First : | 37.52 |
Second : | 45.41 |
| Pivot price | 30.74 |
|||
| Supports | First : | 24.75 | Second : | 20.59 |
| MAs | MA(5) : | 29.34 |
MA(20) : | 32.71 |
| MA(100) : | 42.49 |
MA(250) : | 0 | |
| MACD | MACD : | -4.5 |
Signal : | -4.8 |
| %K %D | K(14,3) : | 28.5 |
D(3) : | 28.7 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 67 | Low : | 6.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MENS ] has closed above bottom band by 35.6%. Bollinger Bands are 50.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 30.01 - 30.2 | 30.2 - 30.37 |
| Low: | 25.84 - 26.03 | 26.03 - 26.21 |
| Close: | 28.88 - 29.19 | 29.19 - 29.48 |
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases.
Tue, 02 Dec 2025
Jyong Biotech Stock (MENS) Opinions on Phase II Trial Results - Quiver Quantitative
Wed, 19 Nov 2025
Jyong Biotech is Now Oversold (MENS) - Nasdaq
Mon, 17 Nov 2025
Google and Micron among market cap stock movers on Monday - Investing.com
Mon, 29 Sep 2025
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
Sat, 26 Jul 2025
Jyong Biotech Stock: Plant‑Based Pipeline Targets Huge Markets Risks Remain (NASDAQ:MENS) - Seeking Alpha
Tue, 01 Jul 2025
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 62.2 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 145 (K) |
| Shares Short P.Month | 142 (K) |
| EPS | -0.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.51 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -730.01 |
| PEG Ratio | 0 |
| Price to Book value | -57.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -613.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|